HOXA2 is a sequence-specific transcription factor that functions as a developmental regulator providing cells with positional identity along the anterior-posterior axis 1. It plays critical roles in hindbrain segmentation and neural crest-derived craniofacial structure patterning 12. HOXA2 activity is regulated through cytoplasmic relocation, protein stabilization, and post-translational modification via interactions with PPP1CB and KPC2 3, and it binds DNA promoter regions to regulate target gene transcription 4. Disease relevance has expanded beyond developmental roles. In cancer, HOXA2 demonstrates context-dependent functions: it acts as an oncogenic transcription factor in prostate cancer, where rs11672691 alters its binding site to enhance PCAT19 and CEACAM21 expression, promoting tumor aggressiveness 5, and as an oncogene in gliomas where high expression correlates with poor prognosis through JAK-STAT pathway activation 6. Conversely, HOXA2 functions as a tumor suppressor in breast cancer, where hypermethylation-induced downregulation increases aggressiveness, while restoration through demethylation suppresses cellular proliferation and promotes apoptosis 7. HOXA2 also protects against renal fibrosis by reducing endoplasmic reticulum stress via SIRT1 upregulation 4. Clinically, HOXA2 expression patterns and epigenetic modifications serve as prognostic biomarkers in multiple malignancies, with potential therapeutic applications in cancer treatment and fibrosis management.